Rothamsted Research seeks permission from the Department for Environment, Food & Rural Affairs for the release of genetically modified Camelina plants for up to three years.

  • 21
  • FEB
  • 2018

“Genetic Improvement of Camelina Seeds” is the title of the field trial that Rothamsted Research hopes to begin this year and complete by 2020, following its application this week to Defra for permission for “the release of genetically modified higher plants” on two of its sites, in Hertfordshire and Suffolk.

The institute has previously field trialled Camelina plants that have been engineered to accumulate the omega-3 long chain polyunsaturated fatty acids (LC-PUFAs), EPA and DHA, and also the ketocarotenoid pigment, astaxanthin, in their seeds.

This work, which the institute began more than 15 years ago to exploit health, environmental and economic benefits, and the currently proposed project are part of ongoing strategic programmes of research at Rothamsted.

In its formal description of the proposed project, Rothamsted notes that Camelina, and specifically Camelina sativa, is an oilseed crop of the Brassicaceae family, whose useful properties include being amenable to genetic improvement. The seed oil of this crop has been modified to accumulate EPA and DHA, the health-beneficial fatty acids that are normally found only in omega-3 fish oils.

Similarly, the seeds of this plant have been modified to accumulate either ketocarotenoids or wax esters, both useful compounds of otherwise limited availability: ketocarotenoids are organic pigments; wax esters are stable, lipid alternatives to petrochemically-derived lubricants.

In addition, two traits related to plant architecture, that is stem thickness and photosynthetic capability, will be evaluated in the field. The goal is to improve Camelina as a crop.

Seeds of camelina Credit: Rothamsted Research Camelina can be genetically engineered to produce seeds containing beneficial fish oils, sustainably relieving the pressure on natural supplies of the oils in the oceans, as well as organic pigments and alternatives to petrochemically-derived lubricants.

Omega-3 LC-PUFAs have been shown to be beneficial for human health and contribute to protection against coronary heart diseases. The primary dietary sources of these fatty acids are marine fish, either wild stocks or farmed fish (aquaculture).

Fish, like humans, do not produce these oils but accumulate them through their diet in the wild or through fishmeal and fish oil in farmed fish. Around 80% of all fish oil is consumed by the aquaculture sector.

Aquaculture, a rapidly expanding modern industry, is seeking new sources of omega-3 LC-PUFAs to ensure its production practices remain sustainable and to nurture the essential aquatic food web. One potential approach is to engineer a crop plant with the capacity to synthesise the fatty acids.

“The omega-3 LC-PUFAs that are beneficial for health are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA),” says Johnathan Napier, Leader of the Omega-3 Camelina Flagship at Rothamsted and visiting professor at the universities of Stirling and Nottingham.

Napier continues: “Plant sources of omega-3, such as flax seed, do not produce EPA and DHA; instead they produce shorter chain omega-3 fatty acids, such as alpha-linolenic acid (ALA). ALA does not confer the health-beneficial properties associated with EPA and DHA, despite the former also being an omega-3 fatty acid. Not all omega-3 fatty acids are equivalent.”

He adds: “We have synthesised the gene sequences involved in the production of omega-3 LC-PUFAs and other useful compounds, such as astaxanthin and wax esters, and optimised them to be functional in Camelina plants.

"These synthetic sequences are based on the sequence of genes found in a range of different organisms, including photosynthetic marine organisms and other lower eukaryote species, such as mosses and oomycetes. By using transgenic Camelina as a chassis to make these useful lipids, we have an alternative source for them.”

GM is just one of many techniques that we use at Rothamsted to address the serious challenges we face to secure an environmentally sustainable supply of food. The GM trial will be less than1% of our experiments in the field this year.

For more information about this trial, go to "GM Camelina Trial: Frequently Asked Questions". For more information on Rothamsted's work on Camelina, go to the impact story, “From oceans to fields and back again”, or go the 2016 report, “Flagship Project: Omega-3 Camelina Development”.

Fluorescencing GM seeds of Camelina Credit: Rothamsted ResearchDsRed fluorescent protein marker identifies GM seeds, containing omega-3 fish oils, among harvested seeds of transgenic Camelina that has been grown in the laboratory

Defra received Rothamsted’s application on Monday, 19 February, from when the department has 90 days to process it (unless the department must stop the clock for any clarification or additional information). The department’s reference for the trial is 18/R08/01.

The statutory 90-day process includes a public consultation (with a representations’ deadline of 8 April) and evaluation of the application by an independent expert group, the Advisory Committee on Releases to the Environment (ACRE). The process might not take as long as 90 days.

The Secretary of State will consider any representations made to him relating to any risks of damage to the environment posed by the release of the genetically modified organisms (GMOs) within a period that he shall specify in accordance with the Genetically Modified Organisms (Deliberate Release) Regulations 2002.

The Secretary of State placed information on this proposed GMO release on a public register within 12 days of his receipt of the application. The public register can be inspected by contacting the Defra GM Team at Nobel House, Smith Square, London SW1P 3JR (e-mail:, and include the application reference number, 18/R08/01, in the e-mail title). This information has also been placed on the GOV.UK website, and is available here.

If granted permission to conduct the field trial, this controlled experiment would be part of Tailoring Plant Metabolism, one of Rothamsted's five strategic programmes (2017-2022) that receive financial support from the Biotechnology and Biological Sciences Research Council.

About Rothamsted Research
Rothamsted Research is the longest-running agricultural research institute in the world. We work from gene to field with a proud history of ground-breaking discoveries, from crop treatment to crop protection, from statistical interpretation to soils management. Our founders, in 1843, were the pioneers of modern agriculture, and we are known for our imaginative science and our collaborative influence on fresh thinking and farming practices.
Through independent science and innovation, we make significant contributions to improving agri-food systems in the UK and internationally. In terms of the institute’s economic contribution, the cumulative impact of our work in the UK was calculated to exceed £3000 million a year in 20151. Our strength lies in our systems approach, which combines science and strategic research, interdisciplinary teams and partnerships.
Rothamsted is also home to three unique resources. These National Capabilities are open to researchers from all over the world: The Long-Term Experiments, Rothamsted Insect Survey and the North Wyke Farm Platform.
We are strategically funded by the Biotechnology and Biological Sciences Research Council (BBSRC), with additional support from other national and international funding streams, and from industry. We are also supported by the Lawes Agricultural Trust (LAT).
For more information, visit; Twitter @Rothamsted
1Rothamsted Research and the Value of Excellence: A synthesis of the available evidence, by Séan Rickard (Oct 2015)

The Biotechnology and Biological Sciences Research Council is part of UK Research and Innovation, a non-departmental public body funded by a grant-in-aid from the UK government.
BBSRC invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond.
Funded by government, BBSRC invested £469 million in world-class bioscience in 2016-17. We support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals.
More information about BBSRC, our science and our impact.
More information about BBSRC strategically funded institutes

About LAT
The Lawes Agricultural Trust, established in 1889 by Sir John Bennet Lawes, supports Rothamsted Research’s national and international agricultural science through the provision of land, facilities and funding. LAT, a charitable trust, owns the estates at Harpenden and Broom's Barn, including many of the buildings used by Rothamsted Research. LAT provides an annual research grant to the Director, accommodation for nearly 200 people, and support for fellowships for young scientists from developing countries. LAT also makes capital grants to help modernise facilities at Rothamsted, or invests in new buildings.